Skip to main content
Clinical Trials/2024-518229-13-00
2024-518229-13-00
Active, not recruiting
Phase 1

A clinical study of MK-2828 in healthy people (MK-2828-002)

Merck Sharp & Dohme LLC1 site in 1 country40 target enrollmentStarted: December 20, 2024Last updated:

Overview

Phase
Phase 1
Status
Active, not recruiting
Enrollment
40
Locations
1

Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages
18 years to 64 years (18-64 Years)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Pharmaceutical company
Responsible Party
Principal Investigator
Principal Investigator

Kiki Cunningham-Bussel

Scientific

Merck Sharp & Dohme LLC

Study Sites (1)

Loading locations...

Similar Trials